

**Table. Change in MCSF From Pre-randomization Baseline in Patients Turning 18 Years Just Before First Dose in the Open-Label Extension (Patients 8-14)**

<b>Patient</b>	<b>Randomized Dose (mg/kg/day FFA)</b>	<b>RCT Percent Change From Baseline (T+M)</b>	<b>OLE Treatment Duration (days)</b>	<b>OLE Percent Change From Pre-randomization Baseline</b>
8	Placebo	-19.7	832	-98.0
9	0.2	-88.7	905	-96.6
10	Placebo	33.3	878	-73.4
11	Study 3 <sup>a</sup>	-47.5	447	-72.6
12	Study 3 <sup>a</sup>	-37.5	722	-59.0
13	Study 3 <sup>a</sup>	-31.4	733	5.4
14	Study 3 <sup>a</sup>	-46.2	30	176.9
<b>Median</b>		<b>-37.5</b>	<b>733</b>	<b>-72.6</b>
<b>(Range)</b>		<b>(-88.7, 33.3)</b>	<b>30, 905</b>	<b>(-98.0, 176.9)</b>

<sup>a</sup>Study 3, Patients were still blinded at time of analysis. FFA, fenfluramine; OLE, open-label extension; T+M, combined titration and maintenance periods.